Question special
Chief Resident

The SALT-ED and SMART trials demonstrated that administration of balanced-crystalloids was associated with a lower risk of adverse kidney events as compared to saline in patients. Importantly, this was shown in patients who were critically ill as well as patients who were not critically ill. How will the results of the SALT-ED and SMART trials affect the standard of care Vanderbilt University Medical Center with regard to intravenous fluid administration? Will balanced-crystalloids become the preferred intravenous fluid for patients in the ER and the ICU?